Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorgenmeltucel-L with Checkpoint Inhibitors in Melanoma
NCT02054520Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jun 2014
- Primary completion
- Apr 2018
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of dorgenmeltucel-L in melanoma, sponsored by Lumos Pharma, Inc.. Started Jun 2014; status: terminated.
02
Drugs
dorgenmeltucel-L
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02054520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054520.